ESTRO 2022 - Abstract Book

S1128

Abstract book

ESTRO 2022

PO-1332 Early menopause induced by oncological treatments in breast and cervical cancer

R. Ching-López 1 , P. Vargas 2 , S. Rodríguez 2 , L. Cámara 3 , P. Galván 2 , A.M. Ruiz 2 , M. Zurita 2

1 Hospital Universitario Virgen de las Nieves, Radiation Oncology , Granada, Spain; 2 Hospital Universitario Virgen de las Nieves, Radiation Oncology, Granada, Spain; 3 Hospital Universitario Virgen de las Nieves, Nursing Department, Obstetrics & Gynecology, Granada, Spain

Purpose or Objective To evaluate the impact on quality of life (QoL) in women diagnosed with breast or cervical cancer under 40 years of age after completing different cancer treatments in a single institution, in terms of genitourinary syndrome (GSM) associated to early treatmentinduced menopause, and to expose the imperative need for a holistic approach to young female cancer patients. Materials and Methods We retrospectively reviewed a total of 31 female patients diagnosed in our centre with breast or cervical cancer under 40 years old who had completed systemic treatment or pelvic radiation therapy between January 2018 and January 2021. They filled out the QOL-C30 survey (version 3) of the European Organization for Research and Treatment of Cancer (EORTC) and the Menopause Rating Scale (MRS), validated in Spanish. Results 13 patients were diagnosed with breast cancer and 18 had cervical cancer. Most of the patients (87.1%) referred serious or extremely serious sexual problems (change in sexual desire, in sexual activity and satisfaction), 61.3% marked bladder problems, (difficulty in urinating, increased need to urinate, bladder incontinence) and 83.8% complained about dryness of vagina (sensation of dryness or burning in the vagina, difficulty with sexual intercourse). Classified by different treatments received, 100% of the patients who underwent pelvic surgery and 100% of patients treated with pelvic radiotherapy +/- brachytherapy indicated "extremely severe" in the presence of vaginal dryness, compared to 73.7% of the patients who received chemotherapy, and only 33.3% of breast cancer patients treated with exclusive hormonal therapy.